Dydrogesterone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317761

CAS#: 152-62-5

Description: Dydrogesterone is a synthetic progestin. Dydrogesterone alone or in combination with estrogen to endothelial cells results in neutral effects on NO synthesis and on the activity and expression of eNOS. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

Chemical Structure

img
Dydrogesterone
CAS# 152-62-5
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317761
Name: Dydrogesterone
CAS#: 152-62-5
Chemical Formula: C21H28O2
Exact Mass: 312.21
Molecular Weight: 312.453
Elemental Analysis: C, 80.73; H, 9.03; O, 10.24

Price and Availability

Size Price Availability Quantity
25mg USD 275 2 weeks
50mg USD 485
Bulk inquiry

Synonym: Dydrogesterone; Isopregnenone; Hydrogesterone; Duphaston; Hydrogestrone; Dufaston; Isopregnenone; Solvay Brand of Dydrogesterone;

IUPAC/Chemical Name: (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one

InChi Key: JGMOKGBVKVMRFX-HQZYFCCVSA-N

InChi Code: InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1

SMILES Code: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Dydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.
In vitro activity: This study found that dydrogesterone resembled progesterone mainly in its progestogenic effects and less in its androgenic, anti-androgenic, glucocorticoid and antiglucocorticoid effects; whereas, 20α-dihydrodydrogesterone showed reduced progestogenic potency with no androgenic, glucocorticoid and mineralocorticoid effects. Reference: Steroids. 2011 May;76(6):607-15. https://pubmed.ncbi.nlm.nih.gov/21376746/
In vivo activity: On gestation Day 13, a highly elevated abortion rate was detected in stressed mice compared to control mice. Stressed animals presented lower levels of progesterone and PIBF in plasma and a reduced staining intensity of progesterone receptor at the feto-maternal interface. Injection of dydrogesterone abrogated the effect of stress on the abortion rate. Further, dydrogesterone increased levels of plasma PIBF in stressed mice, but did not affect progesterone levels. Interestingly, dydrogesterone dramatically increased the percentage of IL-4 positive decidual immune cells in stressed mice. These data suggest that dydrogesterone abrogates stress-triggered abortion by inducing a Th2 biased local immune response. Reference: Steroids. 2003 Nov;68(10-13):931-40. https://pubmed.ncbi.nlm.nih.gov/14667986/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 47.7 152.55
Ethanol 62.0 198.43

Preparing Stock Solutions

The following data is based on the product molecular weight 312.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Fu XD, Garibaldi S, Gopal S, Polak K, Palla G, Spina S, Mannella P, Genazzani AR, Genazzani AD, Simoncini T. Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Mol Hum Reprod. 2012 Jan;18(1):44-51. doi: 10.1093/molehr/gar062. Epub 2011 Oct 4. PMID: 21971309. 2. Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, van der Burg B, Böcker C, Husen B. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011 May;76(6):607-15. doi: 10.1016/j.steroids.2011.02.043. Epub 2011 Mar 3. PMID: 21376746. 3. Jiang YX, Shi WJ, Hu LX, Ma DD, Zhang H, Ong CN, Ying GG. Dydrogesterone disrupts lipid metabolism in zebrafish brain: A study based on metabolomics and Fourier transform infrared spectroscopy. Environ Pollut. 2023 Jan 15;317:120811. doi: 10.1016/j.envpol.2022.120811. Epub 2022 Dec 2. PMID: 36470458. 4. Joachim R, Zenclussen AC, Polgar B, Douglas AJ, Fest S, Knackstedt M, Klapp BF, Arck PC. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids. 2003 Nov;68(10-13):931-40. doi: 10.1016/j.steroids.2003.08.010. PMID: 14667986.
In vitro protocol: 1. Fu XD, Garibaldi S, Gopal S, Polak K, Palla G, Spina S, Mannella P, Genazzani AR, Genazzani AD, Simoncini T. Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Mol Hum Reprod. 2012 Jan;18(1):44-51. doi: 10.1093/molehr/gar062. Epub 2011 Oct 4. PMID: 21971309. 2. Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, van der Burg B, Böcker C, Husen B. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011 May;76(6):607-15. doi: 10.1016/j.steroids.2011.02.043. Epub 2011 Mar 3. PMID: 21376746.
In vivo protocol: 1. Jiang YX, Shi WJ, Hu LX, Ma DD, Zhang H, Ong CN, Ying GG. Dydrogesterone disrupts lipid metabolism in zebrafish brain: A study based on metabolomics and Fourier transform infrared spectroscopy. Environ Pollut. 2023 Jan 15;317:120811. doi: 10.1016/j.envpol.2022.120811. Epub 2022 Dec 2. PMID: 36470458. 2. Joachim R, Zenclussen AC, Polgar B, Douglas AJ, Fest S, Knackstedt M, Klapp BF, Arck PC. The progesterone derivative dydrogesterone abrogates murine stress-triggered abortion by inducing a Th2 biased local immune response. Steroids. 2003 Nov;68(10-13):931-40. doi: 10.1016/j.steroids.2003.08.010. PMID: 14667986.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L,
Seif S, Baheiraei N. A comparative study of dydrogesterone and micronized
progesterone for luteal phase support during in vitro fertilization (IVF) cycles.
Gynecol Endocrinol. 2015 Nov 20:1-5. [Epub ahead of print] PubMed PMID: 26486011.


2: Raghupathy R, Al-Azemi M. Modulation of Cytokine Production by the
Dydrogesterone Metabolite Dihydrodydrogesterone. Am J Reprod Immunol. 2015
Nov;74(5):419-26. doi: 10.1111/aji.12418. Epub 2015 Aug 7. PubMed PMID: 26250154.


3: Podzolkova N, Tatarchuk T, Doshchanova A, Eshimbetova G, Pexman-Fieth C.
Dydrogesterone treatment for menstrual-cycle regularization in routine clinical
practice: a multicenter observational study. Gynecol Endocrinol. 2015 Nov 27:1-4.
[Epub ahead of print] PubMed PMID: 26613278.


4: Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP.
Dydrogesterone versus progesterone for luteal-phase support: systematic review
and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol.
2015 Nov 18. doi: 10.1002/uog.15814. [Epub ahead of print] Review. PubMed PMID:
26577241.


5: Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The Impact of
Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy.
Pediatr Cardiol. 2015 Oct;36(7):1483-8. doi: 10.1007/s00246-015-1190-9. Epub 2015
May 15. PubMed PMID: 25972284.


6: Abboud R, Greige-Gerges H, Charcosset C. Effect of Progesterone, Its
Hydroxylated and Methylated Derivatives, and Dydrogesterone on Lipid Bilayer
Membranes. J Membr Biol. 2015 Aug;248(4):811-24. doi: 10.1007/s00232-015-9803-z.
Epub 2015 Apr 25. PubMed PMID: 25911547.


7: Khosravi D, Taheripanah R, Taheripanah A, Tarighat Monfared V, Hosseini-Zijoud
SM. Comparison of oral dydrogesterone with vaginal progesteronefor luteal support
in IUI cycles: a randomized clinical trial. Iran J Reprod Med. 2015
Jul;13(7):433-8. PubMed PMID: 26494991; PubMed Central PMCID: PMC4609323.


8: Carp H. A systematic review of dydrogesterone for the treatment of recurrent
miscarriage. Gynecol Endocrinol. 2015 Jun;31(6):422-30. doi:
10.3109/09513590.2015.1006618. Epub 2015 Mar 13. PubMed PMID: 25765519.


9: Zhao Y, Castiglioni S, Fent K. Synthetic progestins medroxyprogesterone
acetate and dydrogesterone and their binary mixtures adversely affect
reproduction and lead to histological and transcriptional alterations in
zebrafish (Danio rerio). Environ Sci Technol. 2015 Apr 7;49(7):4636-45. doi:
10.1021/es505575v. Epub 2015 Mar 17. PubMed PMID: 25742325.


10: Liu J, Lin H, Huang Y, Liu Y, Wang B, Su F. Cognitive effects of long-term
dydrogesterone treatment used alone or with estrogen on rat menopausal models of
different ages. Neuroscience. 2015 Apr 2;290:103-14. doi:
10.1016/j.neuroscience.2015.01.042. Epub 2015 Jan 28. PubMed PMID: 25637796.


11: Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus
vaginal progesterone gel in the luteal phase support: randomized controlled
trial. Eur J Obstet Gynecol Reprod Biol. 2015 Mar;186:49-53. doi:
10.1016/j.ejogrb.2014.11.002. Epub 2014 Nov 20. PubMed PMID: 25622239.


12: El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, Mohamed Mel S.
Levonorgestrel-releasing intrauterine device versus dydrogesterone for management
of endometrial hyperplasia without atypia. Reprod Sci. 2015 Mar;22(3):329-34.
doi: 10.1177/1933719114542014. Epub 2014 Jul 6. PubMed PMID: 25001020.


13: Azizuddin, Saima Rasheed SR, Naz S, Naheed S, Choudhary MI. Comparative
anti-glycation and α-glucosidase inhibition studies of microbial transformed
compounds of dydrogesterone. Pak J Pharm Sci. 2015 Mar;28(2):521-3. PubMed PMID:
25730784.


14: Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone
treatment during early pregnancy to prevent recurrent pregnancy loss and its role
in modulation of cytokine production: a double-blind, randomized, parallel,
placebo-controlled trial. Fertil Steril. 2014 Nov;102(5):1357-1363.e3. doi:
10.1016/j.fertnstert.2014.07.1251. Epub 2014 Sep 17. PubMed PMID: 25241364.


15: Ghosh S, Chattopadhyay R, Goswami S, Chaudhury K, Chakravarty B, Ganesh A.
Assessment of sub-endometrial blood flow parameters following dydrogesterone and
micronized vaginal progesterone administration in women with idiopathic recurrent
miscarriage: a pilot study. J Obstet Gynaecol Res. 2014 Jul;40(7):1871-6. doi:
10.1111/jog.12456. PubMed PMID: 25056464.


16: Matsui S, Yasui T, Tani A, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Arisawa
K, Irahara M. Effect of ultra-low-dose estradiol and dydrogesterone on arterial
stiffness in postmenopausal women. Climacteric. 2014 Apr;17(2):191-6. doi:
10.3109/13697137.2013.856399. Epub 2013 Dec 16. PubMed PMID: 24164272.


17: Zainul Rashid MR, Lim JF, Nawawi NH, Luqman M, Zolkeplai MF, Rangkuty HS,
Mohamad Nor NA, Tamil A, Shah SA, Tham SW, Schindler AE. A pilot study to
determine whether progestogen supplementation using dydrogesterone during the
first trimester will reduce the incidence of gestational hypertension in
primigravidae. Gynecol Endocrinol. 2014 Mar;30(3):217-20. doi:
10.3109/09513590.2013.860960. PubMed PMID: 24552449.


18: Rizzo MR, Leo S, De Franciscis P, Colacurci N, Paolisso G. Short-term effects
of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic
fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014
Feb;36(1):265-74. doi: 10.1007/s11357-013-9554-7. Epub 2013 Jul 7. PubMed PMID:
23832170; PubMed Central PMCID: PMC3889904.


19: Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with
suppository vaginal progesterone for luteal-phase support in in vitro
fertilization (IVF): A randomized clinical trial. Iran J Reprod Med. 2013
Nov;11(11):913-8. PubMed PMID: 24639716; PubMed Central PMCID: PMC3941387.


20: Akashi D, Todo Y, Shimada C, Okamoto K, Minobe S, Kato H. Successful use of
dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a
case report. Jpn J Clin Oncol. 2013 Nov;43(11):1145-9. doi: 10.1093/jjco/hyt142.
Epub 2013 Sep 19. PubMed PMID: 24058200.